Compare New York Times Co (NYT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs GeneDx Holdings Corp — how do they compare? New York Times Co trades at $66.8 (market cap $10.96B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: New York Times Co is far larger — about 4.3× GeneDx Holdings Corp's market cap, and New York Times Co pays a 1.35% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NYT | WGS | |
|---|---|---|
Market Cap | $10.96B | $2.56B |
Sector | Media | Technology |
52-Week High | $85.86 | $167.51 |
52-Week Low | $54.66 | $34.51 |
Enterprise Value | $10.36B | $2.60B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal and mixed moving averages. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.69 exceeding the $0.663 forecast. Revenue growth is steady, rising from $2.3B in 2022 to $2.8B in 2025, with net profit margins improving to 12.17%. The company maintains strong cash flow from operations at $584.49M in 2025. Analyst consensus is a $76.00 price target, though the majority recommend Hold.
Outlook remains cautiously optimistic given earnings momentum and solid fundamentals, but risks include the ongoing OpenAI copyright lawsuit and competitive pressures in digital media. The stock offers potential upside to the consensus target, supported by institutional buying interest, though sentiment is tempered by regulatory and litigation uncertainties.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
